Back to Journals » Substance Abuse and Rehabilitation » Volume 3 » Supplement 1

Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes

Authors Lund IO, Fitzsimons H, Tuten M, Chisolm MS, O`Grady KE, Jones HE

Received 18 September 2011

Accepted for publication 7 November 2011

Published 1 February 2012 Volume 2012:3(Supplement 1) Pages 17—25

DOI https://doi.org/10.2147/SAR.S26288

Review by Single-blind

Peer reviewer comments 3

Ingunn O Lund1, Heather Fitzsimons2, Michelle Tuten2, Margaret S Chisolm2, Kevin E O’Grady3, Hendrée E Jones2,4

1SERAF-Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway; 2Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; 3Department of Psychology, University of Maryland, College Park, MD; 4Substance Abuse Treatment Evaluations and Interventions Research Program, RTI International, Research Triangle Park, NC, USA

Abstract: Pregnancy can motivate opioid-dependent women to seek substance abuse treatment. Research has demonstrated that although prenatal exposure to buprenorphine results in less severe neonatal abstinence syndrome (NAS) relative to prenatal methadone exposure, the maternal and other neonatal outcomes are similar for the two medications. Maternal and neonatal outcomes for opioid-dependent pregnant women receiving these medications have not been systematically compared with methadone-assisted withdrawal. The present study provides an initial assessment of the relative efficacy of both methadone and buprenorphine maintenance versus methadone-assisted withdrawal in terms of neonatal and maternal delivery outcomes. Data were derived from (1) the MOTHER (Maternal Opioid Treatment: Human Experimental Research) study at the Johns Hopkins University Bayview Medical Center (JHBMC), or (2) retrospective records review of women who underwent methadone-assisted withdrawal at the JHBMC during the time period in which participants were enrolled in the MOTHER study. Compared with the methadone maintenance group, the methadone-assisted withdrawal group had a significantly lower mean NAS peak score (Means = 13.7 vs 7.0; P = 0.002), required a significantly lower mean amount of morphine to treat NAS (Means = 82.8 vs 0.2; P < 0.001), had significantly fewer days medicated for NAS (Means = 31.5 vs 3.9; P < 0.001), and remained in the hospital for a significantly fewer number of days, on average (Means = 24.2 vs 7.0; P < 0.019). Compared with the buprenorphine maintenance group, the methadone-assisted withdrawal group required a significantly lower mean amount of morphine to treat NAS (Means = 8.2 vs 0.2; P < 0.001) and significantly fewer days medicated for NAS (Means = 12.0 vs 3.9; P = 0.008). Findings suggest that it is possible for some opioid-dependent pregnant women to succeed with methadone-assisted withdrawal. Future research needs to more fully evaluate the potential benefits and risks of methadone-assisted withdrawal for the maternal-fetal dyad.

Keywords: pregnancy, methadone, buprenorphine, detoxification, women, neonates

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Prevention interventions for human immunodeficiency virus in drug-using women with a history of partner violence

Stockman JK, Ludwig-Barron N, Hoffman MA, Ulibarri MD, Penniman Dyer TV

Substance Abuse and Rehabilitation 2012, 3:45-57

Published Date: 1 February 2012

Six-month follow-up of Iranian women in methadone treatment: drug use, social functioning, crime, and HIV and HCV seroincidence

Dolan K, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop D, Mokri A

Substance Abuse and Rehabilitation 2012, 3:37-43

Published Date: 1 February 2012

Naltrexone extended-release injection: an option for the management of opioid abuse

Taylor Jr R, Raffa RB, Pergolizzi Jr JV

Substance Abuse and Rehabilitation 2011, 2:219-226

Published Date: 6 December 2011

Selective review and commentary on emerging pharmacotherapies for opioid addiction

Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K

Substance Abuse and Rehabilitation 2011, 2:181-188

Published Date: 28 October 2011